OPIOID USE AND PREGNANCY

WB4731

PROGRAM DESCRIPTION: This training provides essential knowledge needed to effectively address opioid use before pregnancy, during pregnancy, and in the postpartum period. The training module highlights considerations for initiating opioid therapy for pain for persons who can become pregnant or who are pregnant and presents recommendations for pain management and effective strategies for treating opioid use disorder in pregnant and postpartum persons.

OBJECTIVES:

At the conclusion of the session, the participant should be able to:

- 1. Determine what to consider when initiating opioid therapy for pain for people who may become pregnant or who are pregnant.
- 2. Differentiate between pain management recommendations for individuals during pregnancy and those in the postpartum period.
- 3. Differentiate between strategies for treating opioid use disorder (OUD) in individuals who are pregnant and those in the postpartum period.
- 4. Recognize the importance of care coordination and interprofessional collaboration in pain management and OUD treatment for pregnant and postpartum people.

FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH, Lead Medical Officer, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

Molly Dowling, MPH, Health Communications Specialist, Division of Overdose Prevention, National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention

ORIGINATION DATE: 10/19/2023 EXPIRATION DATE: 10/19/2025

URL: https://www.cdc.gov/opioids/healthcare-professionals/training/Pregnancy.html

HARDWARE/SOFTWARE: Computer Hardware; Internet Connection;

Browser

MATERIALS: None

TARGET AUDIENCE: Physicians, Registered Nurses

PREREQUISITES: None

FORMAT: This activity is **Web-based**.

CONTACT INFORMATION: Division of Overdose Prevention, National

Center for Injury Prevention and Control 800-232-4636

Updated: 2/14/2022 Page 1 of 2

ACCREDITATION STATEMENTS:



In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **0.75** AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **0.75** nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4731 Opioid Use and Pregnancy** please visit <u>TCEO</u> and follow these <u>9 Simple Steps</u> before **10/19/2025**.

Complete the activity
Complete the Evaluation at www.cdc.gov/GetCE
Pass the posttest at 80% at www.cdc.gov/GetCE

FEES: No fees are charged for CDC's CE activities.

Updated: 2/14/2022 Page 2 of 2